Straits Times Index
3,330.77 -0.04 (-0.00%) Nikkei
38,683.93 -19.58 (-0.05%) Hang Seng
18,366.95 -109.85 (-0.59%) FTSE 100
8,245.37 -39.97 (-0.48%) Bitcoin USD
69,291.27 -25.08 (-0.04%) CMC Crypto 200
1,440.12 -38.59 (-2.61%)
GILD Jun 2024 53.000 call
| Previous close | 12.10 |
| Open | 12.10 |
| Bid | 10.05 |
| Ask | 14.00 |
| Strike | 53.00 |
| Expiry date | 2024-06-07 |
| Day's range | 12.10 - 12.10 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
ZacksGilead Sciences (GILD) Gains As Market Dips: What You Should Know
Gilead Sciences (GILD) reachead $64.70 at the closing of the latest trading day, reflecting a +1.33% change compared to its last close.
ZacksInvestors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Business WireGilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA
FOSTER CITY, Calif., June 06, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from the Phase 2b MYR204 open-label study assessing the efficacy and safety of the first-in-class entry inhibitor bulevirtide as monotherapy and in combination with pegylated interferon alfa-2a (PegIFN), in adults living with compensated chronic hepatitis delta virus (HDV) infection. Published in the New England Journal of Medicine (NEJM), the data demonstrate that the investigational combination of bul
